GW Pharmaceuticals’ Epidiolex (cannabidiol) Receives FDA Approval for Epilepsy for 2yrs. or older

Shots:

• The approval is based on three P-III studies results assessing Epidiolex (cannabidiol, PO) vs PBO in 516 patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome aged ≥ 2yrs.
• The study demonstrated in reduction in frequency of seizures
• Epidiolex (cannabidiol, PO) is an oral anti-epileptic drug and has received FDA’s PR, FT, & OD designation on 27 Jun, 2018, Jun, 2014, & 28 Feb, 2014 respectively and has also received EMA’s ODD for treating west syndrome & TSC

Click here to read full press release/ article | Ref: GW Pharmaceuticals | Image: Hempbizjournal